Metastatic Castrate-Resistant Prostate Cancer

The phase 3 PROpel trial provided the primary supporting data for the approval.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery.

"We anticipate that in the next decade, breakthroughs in genetic profiling of tumors for precision therapies will further reduce suffering and death from bladder cancer," writes Michael S. Cookson, MD, MMHC.